Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06898983 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jun 30, 2026 → Jan 31, 2027
See other at-risk trials from Anhui Provincial Hospital

Record History

  1. Primary completion pushed from Jun 30, 2026 to Jan 31, 2027v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 31, 2025 to Jul 14, 2025
    • Site details revised
    v3
  3. Study Status, Contacts/Locationsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluation of the Efficacy and Safety of Romiplostim N01 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (CTIT) in Patients with Leukemia
Trial Details
NCT Number NCT06898983
Lead Sponsor Anhui Provincial Hospital
Conditions
(from sponsor)		 Cancer Treatment-induced Thrombocytopenia (CTIT)
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov